Latest & greatest articles for schizophrenia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on schizophrenia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on schizophrenia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for schizophrenia

41. A systematic review and meta-analysis: post-mortem hippocampal subfield volume, neuronal number, and neuronal density in schizophrenia and control subjects

A systematic review and meta-analysis: post-mortem hippocampal subfield volume, neuronal number, and neuronal density in schizophrenia and control subjects Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

42. Olanzapine versus placebo for people with schizophrenia [Cochrane protocol]

Olanzapine versus placebo for people with schizophrenia [Cochrane protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email

2019 PROSPERO

43. Olanzapine dose for people with schizophrenia [Cochrane protocol]

Olanzapine dose for people with schizophrenia [Cochrane protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g

2019 PROSPERO

44. NAA in schizophrenia, first episode psychosis and high risk mental state: a systematic review and meta-analysis of proton magnetic resonance studies

NAA in schizophrenia, first episode psychosis and high risk mental state: a systematic review and meta-analysis of proton magnetic resonance studies Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

45. Pharmacological interventions for reduction of weight gain in people with schizophrenia [Cochrane protocol]

Pharmacological interventions for reduction of weight gain in people with schizophrenia [Cochrane protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

46. Pharmacological interventions for prevention of weight gain in people with schizophrenia [Cochrane protocol]

Pharmacological interventions for prevention of weight gain in people with schizophrenia [Cochrane protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

47. Pharmacogenomics of antipsychotic response: a systematic review and meta-analysis of polygenic risk scores for schizophrenia

Pharmacogenomics of antipsychotic response: a systematic review and meta-analysis of polygenic risk scores for schizophrenia Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

48. Humour-based interventions for people with schizophrenia [Cochrane protocol]

Humour-based interventions for people with schizophrenia [Cochrane protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email

2019 PROSPERO

49. Healthcare and societal costs for patients with negative symptoms of schizophrenia: a systematic literature review

Healthcare and societal costs for patients with negative symptoms of schizophrenia: a systematic literature review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated

2019 PROSPERO

50. Anti-depressive effect of antipsychotics in the treatment of schizophrenia: systematic review and meta-analysis of randomized placebo-controlled trials

Anti-depressive effect of antipsychotics in the treatment of schizophrenia: systematic review and meta-analysis of randomized placebo-controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

51. The prevalence of aggression in patients with schizophrenia estimated by using modified overt aggression scale: a systematic review and meta-analysis

The prevalence of aggression in patients with schizophrenia estimated by using modified overt aggression scale: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

52. Psychosocial treatments for relapse prevention in schizophrenia. Systematic review and network meta-analysis

Psychosocial treatments for relapse prevention in schizophrenia. Systematic review and network meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

53. Progressive structural brain changes in schizophrenia, bipolar disorder, and major depression disorder related to antipsychotic treatment: a systematic review and meta-analysis update

Progressive structural brain changes in schizophrenia, bipolar disorder, and major depression disorder related to antipsychotic treatment: a systematic review and meta-analysis update Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility

2019 PROSPERO

54. Rates of treatment refractory schizophrenia

Rates of treatment refractory schizophrenia Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2019 PROSPERO

55. The central executive network in schizophrenia: a meta-analysis of structural and functional MRI

The central executive network in schizophrenia: a meta-analysis of structural and functional MRI Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external

2019 PROSPERO

56. The association between motor and cognitive alterations in schizophrenia-spectrum disorders: a systematic review

The association between motor and cognitive alterations in schizophrenia-spectrum disorders: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated

2019 PROSPERO

57. Effectiveness of drug treatments in patients with schizophrenia: a systematic review and network meta-analysis

Effectiveness of drug treatments in patients with schizophrenia: a systematic review and network meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

58. Treatment rate for schizophrenia in China: a systematic review and meta-analysis

Treatment rate for schizophrenia in China: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email

2019 PROSPERO

59. Long-acting injectable vs oral antipsychotics for preventing rehospitalization in schizophrenia: a meta-analysis of randomized, mirror-image, and cohort studies

Long-acting injectable vs oral antipsychotics for preventing rehospitalization in schizophrenia: a meta-analysis of randomized, mirror-image, and cohort studies Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

60. Optimal dose of antipsychotic drugs in schizophrenia: a systematic review and dose-response meta-analysis

Optimal dose of antipsychotic drugs in schizophrenia: a systematic review and dose-response meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO